Wells Fargo Securities, the investment banking and capital markets business of Wells Fargo & Company, announced that Andrew Singer has joined as managing director focused on the biopharmaceutical industry. He will be based in San Francisco.
 
“We are excited to have Andy join us, as he brings a unique perspective that will be impactful to our clients,” said John Hudson, co-head of Investment Banking Coverage at Wells Fargo Securities. “As a veteran investment banker and former chief financial officer, he will complement and enhance our existing biopharmaceutical coverage team. His addition reaffirms our commitment to this sector, which is one of the fastest growing on our investment banking platform.”
 
Singer joins Wells Fargo from Epizyme, a biopharmaceutical company focused on creating novel therapeutics for patients with genetically defined cancers, where he served as executive vice president, finance and administration, and chief financial officer. Previously, he was a managing director in the Life Sciences Group at RBC Capital Markets. Earlier, Singer also worked at Robertson, Stephens, The Shansby Group and The Blackstone Group.
 
He is a member of the board of directors of the J. F. Kapnek Trust, a leading provider of services for the prevention of mother-to-child HIV transmission and other programs for vulnerable children in Zimbabwe.
 
Singer received a B.A. from Yale University and an M.B.A. from Harvard University Graduate School of Business.